Kilitch Drugs Bonus Shares 1:1, Q3 Results, Share Price

As of February 13, 2026 (09:38 IST), the stock was trading at ₹333.25, up ₹3.25 (0.98%). The stock has delivered a 7.04% return over one year and 134.11% return over three years.

Kilitch Drugs (India) 1:1 Bonus Issue and Capital Expansion

The company has recommended issuing one bonus equity share of ₹10 each for every one existing fully paid-up equity share held by shareholders. The record date will be announced later.

Following the bonus allotment, the paid-up share capital will double from 1,74,80,782 shares (₹17.48 crore) to 3,49,61,564 shares (₹34.96 crore). The bonus shares will be funded by capitalising internal reserves, including Free Reserves of approximately ₹34.20 crore and a Securities Premium Account of approximately ₹94.13 crore as of December 31, 2025.

The company expects the bonus shares to be credited or dispatched by April 10, 2026, subject to shareholder approval. To facilitate this issuance, the Board also approved increasing the authorised share capital from ₹25 crore to ₹40 crore.

Kilitch Drugs (India) Q3 FY26 Standalone Financial Performance

During Q3 FY26, the company recorded total income of ₹4,627.81 lakhs, compared with ₹4,888.32 lakhs in Q3 FY25, reflecting a 5.33% decline.

Expenses increased slightly, with total expenses rising to ₹4,010.68 lakhs from ₹3,936.41 lakhs, marking a 1.89% increase. As a result, profitability weakened during the quarter. Profit before tax fell 35.17% to ₹617.13 lakhs from ₹951.91 lakhs a year ago, while net profit after tax declined 28.94% to ₹489.08 lakhs from ₹688.30 lakhs.

However, the company reported improved overall earnings quality. Total comprehensive income rose 13.26% to ₹640.12 lakhs, compared with ₹565.20 lakhs in the same quarter last year. Earnings per share for the quarter stood at ₹2.74.

Consolidated Financial Performance

On a consolidated basis, the company reported total income of ₹5,533.61 lakhs, down 4.41% from ₹5,789.13 lakhs in Q3 FY25.

Total expenses remained almost flat, increasing 0.20% to ₹4,974.00 lakhs from ₹4,964.05 lakhs. Profitability pressures were visible here as well, with profit before tax declining 32.17% to ₹559.61 lakhs from ₹825.08 lakhs. Net profit after tax fell 23.14% to ₹431.54 lakhs from ₹561.47 lakhs.

Despite lower profits, the company posted stronger overall gains, as total comprehensive income surged 32.90% to ₹582.57 lakhs, compared with ₹438.37 lakhs in the year-ago quarter.

The consolidated figures include subsidiary operations of Monarchy Healthserve Private Limited and Kilitch Estro Biotech PLC.

Rights Issue and Expansion Project

The company noted recent capital changes following a rights issue in September 2025, through which it raised approximately ₹49.93 crore. The funds are being utilised for a Greenfield Project at Pen.

EGM Details

The company will seek shareholder approval for the bonus issue and capital increase at an Extraordinary General Meeting (EGM) scheduled on Friday, March 13, 2026, at 11:30 A.M., which will be conducted via video conferencing.

Business Overview

Incorporated in 1978, the company operates in pharmaceutical products and is engaged in developing, manufacturing, marketing, and exporting pharmaceutical formulations. Its product portfolio covers multiple dosage forms, including solid, liquid, and parenteral formulations.